Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease ; volume:12 ; number:1 ; day:2 ; month:10 ; year:2020 ; pages:1-13 ; date:12.2020
Alzheimer's research & therapy ; 12, Heft 1 (2.10.2020), 1-13, 12.2020
- Creator
-
Ahmad, Shahzad
Orellana, Adelina
Kohler, Isabelle
Frölich, Lutz
Rojas, Itziar de
Gil, Silvia
Boada, Mercè
Hernández, Isabel
Hausner, Lucrezia
Bakker, Margot H. M.
Cabrera-Socorro, Alfredo
Amin, Najaf
Ramírez, Alfredo
Ruiz, Agustín
Hankemeier, Thomas
Duijn, Cornelia M. Van
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-020-00680-9
- URN
-
urn:nbn:de:101:1-2020112117334336572118
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ahmad, Shahzad
- Orellana, Adelina
- Kohler, Isabelle
- Frölich, Lutz
- Rojas, Itziar de
- Gil, Silvia
- Boada, Mercè
- Hernández, Isabel
- Hausner, Lucrezia
- Bakker, Margot H. M.
- Cabrera-Socorro, Alfredo
- Amin, Najaf
- Ramírez, Alfredo
- Ruiz, Agustín
- Hankemeier, Thomas
- Duijn, Cornelia M. Van
- SpringerLink (Online service)
Other Objects (12)
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
Cerebrospinal Fluid S100B and Alzheimer’s Disease Biomarkers in Hip Fracture Patients with Delirium
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer’s disease
Current state of Alzheimer’s fluid biomarkers
The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
Cerebrospinal Fluid S100B and Alzheimer’s Disease Biomarkers in Hip Fracture Patients with Delirium
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer’s disease
Current state of Alzheimer’s fluid biomarkers
The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
Cerebrospinal Fluid S100B and Alzheimer’s Disease Biomarkers in Hip Fracture Patients with Delirium
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer’s disease
Current state of Alzheimer’s fluid biomarkers